Introduction to eicosanoids and the gastroenteric tract

R. N. Dubois, C. E. Eberhart, C. S. Williams

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Eicosanoids are produced throughout the gastrointestinal tract and are significant mediators of physiologic and pathophysiologic processes. Understanding the precise role(s) of specific eicosanoid metabolites remains a significant challenge, but has led to the development of new pharmacologic strategies for treating NSAID-induced, gastroenteropathy and IBD. Given the complex array of arachidonic acid metabolites, the development of more specific and potent inhibitors of these cyclooxygenase isoforms is important for future studies and possible therapeutic applications. Mice have been prepared that lack expression of COX-1 or COX-2. Once these animals have been carefully evaluated, understanding of the role of various pathways of eicosanoid formation in gastrointestinal function, development, and epithelial growth regulation might be improved. Considerable progress has been made in the understanding of arachidonic acid metabolism and in eicosanoid receptor biology. The identification and characterization of an inducible cyclooxygenase isoform has led to important studies evaluating the role of this enzyme in inflammation, neoplasia, and NSAID-induced gastrointestinal injury. The demonstration that COX-2 overexpression in intestinal epithelial cells leads to specific phenotypic changes, such as increased adhesion and inhibition of apoptosis, indicates that this enzyme may alter the tumorigenic potential of epithelial cells and offers hope for the future development of improved chemopreventive agents.

Original languageEnglish (US)
Pages (from-to)267-277
Number of pages11
JournalGastroenterology Clinics of North America
Volume25
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Eicosanoids
Non-Steroidal Anti-Inflammatory Agents
Arachidonic Acid
Eicosanoid Receptors
Protein Isoforms
Epithelial Cells
Cyclooxygenase Inhibitors
Enzymes
Prostaglandin-Endoperoxide Synthases
Growth and Development
Gastrointestinal Tract
Apoptosis
Inflammation
Wounds and Injuries
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Introduction to eicosanoids and the gastroenteric tract. / Dubois, R. N.; Eberhart, C. E.; Williams, C. S.

In: Gastroenterology Clinics of North America, Vol. 25, No. 2, 1996, p. 267-277.

Research output: Contribution to journalArticle

Dubois, R. N. ; Eberhart, C. E. ; Williams, C. S. / Introduction to eicosanoids and the gastroenteric tract. In: Gastroenterology Clinics of North America. 1996 ; Vol. 25, No. 2. pp. 267-277.
@article{8f3c142ec4f24fe7a0e8ef3f639dab48,
title = "Introduction to eicosanoids and the gastroenteric tract",
abstract = "Eicosanoids are produced throughout the gastrointestinal tract and are significant mediators of physiologic and pathophysiologic processes. Understanding the precise role(s) of specific eicosanoid metabolites remains a significant challenge, but has led to the development of new pharmacologic strategies for treating NSAID-induced, gastroenteropathy and IBD. Given the complex array of arachidonic acid metabolites, the development of more specific and potent inhibitors of these cyclooxygenase isoforms is important for future studies and possible therapeutic applications. Mice have been prepared that lack expression of COX-1 or COX-2. Once these animals have been carefully evaluated, understanding of the role of various pathways of eicosanoid formation in gastrointestinal function, development, and epithelial growth regulation might be improved. Considerable progress has been made in the understanding of arachidonic acid metabolism and in eicosanoid receptor biology. The identification and characterization of an inducible cyclooxygenase isoform has led to important studies evaluating the role of this enzyme in inflammation, neoplasia, and NSAID-induced gastrointestinal injury. The demonstration that COX-2 overexpression in intestinal epithelial cells leads to specific phenotypic changes, such as increased adhesion and inhibition of apoptosis, indicates that this enzyme may alter the tumorigenic potential of epithelial cells and offers hope for the future development of improved chemopreventive agents.",
author = "Dubois, {R. N.} and Eberhart, {C. E.} and Williams, {C. S.}",
year = "1996",
doi = "10.1016/S0889-8553(05)70246-6",
language = "English (US)",
volume = "25",
pages = "267--277",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Introduction to eicosanoids and the gastroenteric tract

AU - Dubois, R. N.

AU - Eberhart, C. E.

AU - Williams, C. S.

PY - 1996

Y1 - 1996

N2 - Eicosanoids are produced throughout the gastrointestinal tract and are significant mediators of physiologic and pathophysiologic processes. Understanding the precise role(s) of specific eicosanoid metabolites remains a significant challenge, but has led to the development of new pharmacologic strategies for treating NSAID-induced, gastroenteropathy and IBD. Given the complex array of arachidonic acid metabolites, the development of more specific and potent inhibitors of these cyclooxygenase isoforms is important for future studies and possible therapeutic applications. Mice have been prepared that lack expression of COX-1 or COX-2. Once these animals have been carefully evaluated, understanding of the role of various pathways of eicosanoid formation in gastrointestinal function, development, and epithelial growth regulation might be improved. Considerable progress has been made in the understanding of arachidonic acid metabolism and in eicosanoid receptor biology. The identification and characterization of an inducible cyclooxygenase isoform has led to important studies evaluating the role of this enzyme in inflammation, neoplasia, and NSAID-induced gastrointestinal injury. The demonstration that COX-2 overexpression in intestinal epithelial cells leads to specific phenotypic changes, such as increased adhesion and inhibition of apoptosis, indicates that this enzyme may alter the tumorigenic potential of epithelial cells and offers hope for the future development of improved chemopreventive agents.

AB - Eicosanoids are produced throughout the gastrointestinal tract and are significant mediators of physiologic and pathophysiologic processes. Understanding the precise role(s) of specific eicosanoid metabolites remains a significant challenge, but has led to the development of new pharmacologic strategies for treating NSAID-induced, gastroenteropathy and IBD. Given the complex array of arachidonic acid metabolites, the development of more specific and potent inhibitors of these cyclooxygenase isoforms is important for future studies and possible therapeutic applications. Mice have been prepared that lack expression of COX-1 or COX-2. Once these animals have been carefully evaluated, understanding of the role of various pathways of eicosanoid formation in gastrointestinal function, development, and epithelial growth regulation might be improved. Considerable progress has been made in the understanding of arachidonic acid metabolism and in eicosanoid receptor biology. The identification and characterization of an inducible cyclooxygenase isoform has led to important studies evaluating the role of this enzyme in inflammation, neoplasia, and NSAID-induced gastrointestinal injury. The demonstration that COX-2 overexpression in intestinal epithelial cells leads to specific phenotypic changes, such as increased adhesion and inhibition of apoptosis, indicates that this enzyme may alter the tumorigenic potential of epithelial cells and offers hope for the future development of improved chemopreventive agents.

UR - http://www.scopus.com/inward/record.url?scp=0029939611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029939611&partnerID=8YFLogxK

U2 - 10.1016/S0889-8553(05)70246-6

DO - 10.1016/S0889-8553(05)70246-6

M3 - Article

C2 - 9229572

AN - SCOPUS:0029939611

VL - 25

SP - 267

EP - 277

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 2

ER -